Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503).
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).
